[1]苏莉,陈璟,赵明.131I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较[J].国际放射医学核医学杂志,2007,31(6):366-369.
　SU Li,CHEN Jing,ZHAO Ming.Clinical evaluation of the treatment in male patient with thyrotoxic periodic paralysis: 131I treatment compared with antithyroid drug therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):366-369.
点击复制

131I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第6期
页码:
366-369
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Clinical evaluation of the treatment in male patient with thyrotoxic periodic paralysis: 131I treatment compared with antithyroid drug therapy
作者:
苏莉1;  陈璟2;  赵明2
1. 432000 湖北, 湖北省孝感市中心医院核医学科;
2. 430030 武汉, 华中科技大学同济医学院附属同济医院核医学科
Author(s):
SU Li1;  CHEN Jing2;  ZHAO Ming2
1. Department of Nuclear Medicine, Central Hospital of Xiao Gan City, Hubei Xiaogan 432000, China;
2. Department of Nuclear Medicine, Tongji Hospital, Tongji Medical. College, Huazhong University of Science and Technology, Wuhan 430030, China
关键词:
甲状腺功能亢进症; 低钾性周期性麻痹; 碘放射性同位素; 抗甲状腺药; 对比研究
Keywords:
Hyperthyroldisim; Hypokalemic periodic paeralysis; Iodine radioisotopes; Antithyroid agents; Comparative study
分类号:
R817.5
摘要:
目的 评价131I治疗男性甲状腺功能亢进症(甲亢)周期性麻痹的临床疗效。方法 100例已确诊的男性甲亢周期性麻痹病例,分成131I治疗组(50例)和抗甲状腺药物(ATD)治疗组(50例),分别治疗后随访3年,比较两组的治疗疗效、甲状腺功能减退症(甲减)发生率、甲亢周期性麻痹的复发率及治疗的副反应(粒细胞减低、肝功能受损、药源性皮疹的发生)。结果 131I治疗组治疗总有效率为80%,高于ATD治疗组(52%),二者差异有极显著性(χ2=8.73,P<0.01);131I治疗组甲亢周期性麻痹的复发率及副反应的发生均明显低于ATD治疗组(χ2=18.92,P<0.01;χ2=11.11,P<0.01);但131I治疗组的甲减发生率高于ATD治疗组(χ2=6.35,P<0.05)。结论 131I治疗明显优于传统的ATD治疗,能有效控制男性甲亢周期性麻痹的反复发作,且用药安全,副反应少。
Abstract:
Objective To evaluate clinical efficacy of 131I treatment for thyrotoxic periodic paralysis. Methods 100 male patients with thyrotoxic periodic paralysis were divided equally into two groups, and treated with 131I or antithyroid drugs (ATD). They were followed up regularly for 3 years with the cure rate, the incidence of hypothyroidism, the recurrence rate of thyrotoxic periodic paralysis and the side effects, which included granulocytopenia, liver function damage and skin rash from medicinal herbs resource. Results The cure rate of 131I therapy and ATD therapy for thyrotoxic periodic paralysis is 80% and 52%, respectively. And there is significant difference between them (χ2=8.73,P<0.01). The group of ATD therapy has a higher recurrence rate of thyrotoxic periodic paralysis and more side effects (χ2=18.92, P<0.01;χ2=11.11, P<0.01). While the group of 131I therapy has a higher incidence of hypothyroidism (χ2=6.35, P<0.01). Conclusions 131I is preferable to effectively control the recurrent attacks of thyrotoxic periodic paralysis.

参考文献/References:

1 江蓓,张宝珠.甲亢肌病的表现及其处理.中国实用内科杂志,1997,17(12):713-714.
2 吴华.核医学临床指南.第1版.北京:科学出版社,1999.182.
3 Dzialowski I, Weber J, Doerfler A, et al. Brain tissue water uptake after middle cerebral artery ocelusion assessed with CT. J Neuroimaging, 2004. 14(1):42-48.
4 Mciver B, Rae P, Beckett G, et al. Lack of effect of thyroxine in patients with Graves, hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996, 334(4):220-224.
5 Kung A, Wlau KS, Fong GC, et al. Asociation of novel single neleotide polymorphisms in the calcium channel α1 subunit gene (Cav1.1) and thyrotoxic periodic paralysis. J Clin Endocrinol Metab, 2004, (3):1340-1345.
6 金美娟,徐建平.甲状腺功能亢进症合并周期性麻痹20例临床分析.现代中西医结合杂志,2006,15(6):738-739.
7 Reisin RC, Martinez O, Moran M, et al. Thyrotoxic periodic paralysis in Caucasians. Report of 8 cases. Neurologia, 2000, 15(6):222-225.
8 Lin SH. Thvrotoxic periodic paralysis. Mayo Clin Proc, 2005, 80(7):960-961.
9 艾比拜·玉素甫,胡尔西达·牙合甫.甲状腺功能亢进合并周期性麻痹51例临床分析.新疆医科大学学报,2004,27(4):416.
10 刘长江,李龙,高健青,等.碘-131治疗甲亢长期随访疗效分析.核技术,2006,29(11):838-841.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[8]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[9]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[10]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
　WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]

备注/Memo

备注/Memo:
收稿日期:2007-07-03。
通讯作者:苏莉,E-mail:suli945@163.com
更新日期/Last Update: 1900-01-01